Pathophysiology of immune thrombocytopenia;Physiopathologie du purpura thrombopénique immunologique

Revue de Medecine Interne

Volumn 32, Issue 6, 2011, Pages 350-357

  Audia, S ^a,b   Lorcerie, B ^a   Godeau, B ^c   Bonnotte, B ^a,b  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Immune thrombocytopenia; Pathogenesis

Indexed keywords

AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CELLULAR IMMUNITY; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; SHORT SURVEY; THROMBOCYTE DISORDER; THROMBOCYTOPENIA;

EID: 79956117899     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.05.017     Document Type: Short Survey

References (83)

1. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
2. Cines D.B., McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 2007, 14:511-514.
3. Cooper N., Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006, 133:364-374.
4. Nomura S., Matsuzaki T., Ozaki Y., Yamaoka M., Yoshimura C., Katsura K., et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 1998, 91:3616-3622.
5. Porges A., Bussel J., Kimberly R., Schulman I., Pollack M., Pandey J., et al. Elevation of platelet associated antibody levels in patients with chronic idiopathic thrombocytopenic purpura expressing the B8 and/or DR3 allotypes. Tissue Antigens 1985, 26:132-137.
6. Maia M.H., Peixoto Rde L., de Lima C.P., Magalhaes M., Sena L., Costa Pdo S., et al. Predisposition to idiopathic thrombocytopenic purpura maps close to the major histocompatibility complex class I chain-related gene A. Hum Immunol 2009, 70:179-183.
7. Castro V., Oliveira G.B., Origa A.F., Annichino-Bizzacchi J.M., Arruda V.R. The human platelet alloantigen 5 polymorphism as a risk for the development of acute idiopathic thrombocytopenia purpura. Thromb Haemost 2000, 84:360-361.
8. Thude H., Gatzka E., Anders O., Barz D. Allele frequencies of human platelet antigen 1, 2, 3, and 5 systems in patients with chronic refractory autoimmune thrombocytopenia and in normal persons. Vox Sang 1999, 77:149-153.
9. Foster C.B., Zhu S., Erichsen H.C., Lehrnbecher T., Hart E.S., Choi E., et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001, 113:596-599.
10. Wu K.H., Peng C.T., Li T.C., Wan L., Tsai C.H., Lan S.J., et al. Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura. Br J Haematol 2005, 128:849-852.
11. Atabay B., Oren H., Irken G., Kizildag S., Tunali S., Turker M., et al. Role of transforming growth factor-beta 1 gene polymorphisms in childhood idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003, 25:885-889.
12. Bossen C., Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006, 18:263-275.
13. Emmerich F., Bal G., Barakat A., Milz J., Muhle C., Martinez-Gamboa L., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007, 136:309-314.
14. Liebman H.A., Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 2007, 14:557-573.
15. Musaji A., Cormont F., Thirion G., Cambiaso C.L., Coutelier J.P. Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. Blood 2004, 104:2102-2106.
16. Musaji A., Meite M., Detalle L., Franquin S., Cormont F., Preat V., et al. Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. Autoimmun Rev 2005, 4:247-252.
17. Stasi R., Provan D. Helicobacter pylori and Chronic ITP. Hematology Am Soc Hematol Educ Program 2008, 2008:206-211.
18. Stasi R., Sarpatwari A., Segal J.B., Osborn J., Evangelista M.L., Cooper N., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009, 113:1231-1240.
19. Takahashi T., Yujiri T., Shinohara K., Inoue Y., Sato Y., Fujii Y., et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004, 124:91-96.
20. Asahi A., Nishimoto T., Okazaki Y., Suzuki H., Masaoka T., Kawakami Y., et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008, 118:2939-2949.
21. Bettaieb A., Oksenhendler E., Duedari N., Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996, 103:19-23.
22. Zhang W., Nardi M.A., Li Z., Borkowsky W., Karpatkin S. Role of molecular mimickry of hepatitis C-virus (HCV) protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009 Apr 23, 113:4086-4093.
23. Liebman H.A. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2008, 2008:212-218.
24. Doi T., Homma H., Mezawa S., Kato J., Kogawa K., Sakamaki S., et al. Mechanisms for increment of platelet associated IgG and platelet surface IgG and their implications in immune thrombocytopenia associated with chronic viral liver disease. Hepatol Res 2002, 24:23.
25. Giannini E., Botta F., Borro P., Malfatti F., Fumagalli A., Testa E., et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003, 98:2516-2520.
26. Harrington W.J., Minnich V., Hollingsworth J.W., Moore C.V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951, 38:1-10.
27. Shulman N.R., Marder V.J., Weinrach R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci 1965, 124:499-542.
28. Kelton J.G., Powers P.J., Carter C.J. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982, 60:1050-1053.
29. Romero-Guzman L.T., Lopez-Karpovitch X., Paredes R., Barrales-Benitez O., Piedras J. Detection of platelet-associated immunoglobulins by flow cytometry for the diagnosis of immune thrombocytopenia: a prospective study and critical review. Haematologica 2000, 85:627-631.
30. Kiefel V., Santoso S., Weisheit M., Mueller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987, 70:1722-1726.
31. He R., Reid D.M., Jones C.E., Shulman N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994, 83:1024-1032.
32. van Leeuwen E.F., van der Ven J.T., Engelfriet C.P., von dem Borne A.E. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982, 59:23-26.
33. Roark J.H., Bussel J.B., Cines D.B., Siegel D.L. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002, 100:1388-1398.
34. Kuwana M., Okazaki Y., Kaburaki J., Kawakami Y., Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002, 168:3675-3682.
35. Patel V.L., Schwartz J., Bussel J.B. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008, 141:545-548.
36. Kuwana M., Kawakami Y., Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 2003, 101:621-623.
37. Solanilla A., Pasquet J.M., Viallard J.F., Contin C., Grosset C., Dechanet-Merville J., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005, 105:215-218.
38. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004, 103:1229-1236.
39. Koyama I., Kawai T., Andrews D., Boskovic S., Nadazdin O., Wee S.L., et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004, 77:460-462.
40. Sidiropoulos P.I., Boumpas D.T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13:391-397.
41. Rand M.L., Dean J.A. Platelet function in autoimmune (idiopathic) thrombocytopenic purpura. Acta Paediatr Suppl 1998, 424:57-60.
42. Rinder H.M., Tracey J.B., Recht M., DeCastro L., Rinder C.S., McHugh C., et al. Differences in platelet alpha-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost 1998, 80:457-462.
43. Kuwana M., Okazaki Y., Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2008.
44. Zhou Z., Chen Z., Li H., Chen X., Xu J., Gu D., et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity 2009, 42:112-119.
45. McMillan R., Longmire R.L., Yelenosky R., Smith R.S., Craddock C.G. Immunoglobulin synthesis in vitro by splenic tissue in idiopathic thrombocytopenic purpura. N Engl J Med 1972, 286:681-684.
46. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 2008, 8:1805-1814.
47. Godeau B., Porcher R., Fain O., Lefrere F., Fenaux P., Cheze S., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura - results of a prospective multicenter phase 2 study. Blood 2008 Aug 15, 112:999-1004.
48. Walshe C.A., Beers S.A., French R.R., Chan C.H., Johnson P.W., Packham G.K., et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008.
49. Panitsas F.P., Theodoropoulou M., Kouraklis A., Karakantza M., Theodorou G.L., Zoumbos N.C., et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004, 103:2645-2647.
50. Stasi R., Del Poeta G., Stipa E., Evangelista M.L., Trawinska M.M., Cooper N., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
51. Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
52. Liu F., Wu C., Yang X., Xiao H., Zhuo X., Cheng Z., et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura. Cell Mol Immunol 2005, 2:387-392.
53. Olsson B., Andersson P.O., Jacobsson S., Carlsson L., Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005, 93:139-144.
54. Abboud M.R., Laver J., Xu F., Weksler B., Bussel J. Serum levels of GM-CSF are elevated in patients with thrombocytopenia. Br J Haematol 1996, 92:486-488.
55. Catani L., Fagioli M.E., Tazzari P.L., Ricci F., Curti A., Rovito M., et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006, 34:879-887.
56. Ware R.E., Howard T.A. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood 1993, 82:2137-2142.
57. Yoshimura C., Nomura S., Nagahama M., Ozaki Y., Kagawa H., Fukuhara S. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura. Eur J Haematol 2000, 64:219-224.
58. Filion M.C., Proulx C., Bradley A.J., Devine D.V., Sekaly R.P., Decary F., et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood 1996, 88:2144-2150.
59. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998, 102:1393-1402.
60. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
61. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
62. Thornton A.M., Shevach E.M. Suppressor effector function of CD4+CD25+immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164:183-190.
63. Thornton A.M., Shevach E.M. CD4+CD25+immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
64. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-116.
65. Askenasy N., Kaminitz A., Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008, 7:370-375.
66. Ling Y., Cao X.S., Yu Z.Q., Luo G.H., Bai X., Su J., et al. Alterations of CD4+CD25+regulatory T cells in patients with idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2007, 28:184-188.
67. Liu B., Zhao H., Poon M.C., Han Z., Gu D., Xu M., et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007, 78:139-143.
68. Stasi R., Cooper N., Del Poeta G., Stipa E., Evangelista M.L., Abruzzese E., et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2008, 15(112):1147-1150.
69. Sakakura M., Wada H., Tawara I., Nobori T., Sugiyama T., Sagawa N., et al. Reduced Cd4+Cd25+T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007, 120:187-193.
70. Yu J., Heck S., Patel V., Levan J., Yu Y., Bussel J.B., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112:1325-1328.
71. Ephrem A., Chamat S., Miquel C., Fisson S., Mouthon L., Caligiuri G., et al. Expansion of CD4+CD25+regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
72. Kessel A., Ammuri H., Peri R., Pavlotzky E.R., Blank M., Shoenfeld Y., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007, 179:5571-5575.
73. Andersson P.O., Olsson A., Wadenvik H. Reduced transforming growth factor-beta1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. Br J Haematol 2002, 116:862-867.
74. McMillan R., Wang L., Tomer A., Nichol J., Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
75. Houwerzijl E.J., Blom N.R., van der Want J.J., Esselink M.T., Koornstra J.J., Smit J.W., et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103:500-506.
76. Houwerzijl E.J., Blom N.R., van der Want J.J., Vellenga E., de Wolf J.T. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006, 20:1937-1942.
77. Olsson B., Ridell B., Carlsson L., Jacobsson S., Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112:1078-1084.
78. Kuwana M., Okazaki Y., Kajihara M., Kaburaki J., Miyazaki H., Kawakami Y., et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002, 46:2148-2159.
79. Kosugi S., Kurata Y., Tomiyama Y., Tahara T., Kato T., Tadokoro S., et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996, 93:704-706.
80. Kuter D.J. The physiology of platelet production. Stem Cells 1996, 14(Suppl. 1):88-101.
81. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
82. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
83. Nurden A.T., Viallard J.F., Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009, [Epub ahead of print].